Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Диагностика почечно-клеточного рака у больных раком предстательной железы: возможности ПЭТ/КТ с 18F-PSMA-1007
Диагностика почечно-клеточного рака у больных раком предстательной железы: возможности ПЭТ/КТ с 18F-PSMA-1007
Огнерубов Н.А., Мирсалимова О.О., Антипова Т.С. Диагностика почечно-клеточного рака у больных раком предстательной железы: возможности ПЭТ/КТ с 18F-PSMA-1007. Современная Онкология. 2025;27(2):130–135. DOI: 10.26442/18151434.2025.2.203318
© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Обоснование. Рак предстательной железы (РПЖ) в структуре заболеваемости и смертности в мире занимает 4 и 8-е место. Среди методов медицинской визуализации комбинированная позитронно-эмиссионная и рентгеновская компьютерная томография (ПЭТ/КТ) с лигандом простат-специфического мембранного антигена является весьма обнадеживающей при РПЖ, почечно-клеточном раке (ПКР), раке легких, молочной железы при стадировании первичной опухоли, оценке эффективности терапии и наблюдении.
Цель. Оценить возможности ПЭТ/КТ с 18F-PSMA-1007 для диагностики первичных опухолей почек у больных РПЖ.
Материалы и методы. Под наблюдением находились 492 пациента с гистологически подтвержденным РПЖ I–IV стадий. Всем больным проводилось обследование с помощью ПЭТ/КТ с 18F-PSMA-1007 на этапе стадирования, в процессе терапии, диспансерном наблюдении и рестадировании при прогрессировании. Исследование выполнялось на аппарате GE Discovery PET/CT 710.
Результаты. У 24 (4,9%) пациентов выявлены первично-множественные злокачественные опухоли различных локализаций. Среди них светлоклеточный ПКР диагностирован в 8 (1,6%) наблюдениях. Медиана возраста составила 73,3 года. В большинстве случаев – у 6 (75%) пациентов – опухоль являлась синхронной и у 2 (25%) имела метахронный характер. Чаще всего опухолевый процесс локализовался в левой почке – 6 (62,5%), а в правой – у 3 (37,5%) больных. В верхнем сегменте опухоль диагностирована в 5 случаях, в переднем – у 2 пациентов и в нижнем сегменте – у 1. Величина первичной опухоли в среднем составляла 33,8 мм, что соответствует категории Т1а. Медиана SUVmax в опухоли – 17,92. При гистологическом исследовании биоптатов из новообразования у всех выявлен светлоклеточный ПКР. На I этапе хирургическое лечение выполнено 7 больным: лапароскопическая нефрэктомия – 2 пациентам и органосохраняющие вмешательства эндоскопическим доступом – 5. Системная терапия назначена 1 больному.
Заключение. ПЭТ/КТ с 18F-PSMA-1007 является альтернативным методом оценки распространенности опухолевого процесса у больных РПЖ на этапах лечебно-диагностического процесса. Он позволяет в 1,6% случаев выявить первично-множественные опухоли почек. Их величина в среднем составила 33,8 мм, что соответствует стадии Т1а. В таких случаях лечение необходимо начинать с хирургического вмешательства, что позволяет персонализировать лечебные опции.
Ключевые слова: рак предстательной железы, светлоклеточный почечно-клеточный рак, диагностика, комбинированная позитронно- эмиссионная и рентгеновская компьютерная томография с 18F-PSMA-1007
Aim. To evaluate the capabilities of PET/CT with 18F-PSMA-1007 for the diagnosis of primary renal tumors in patients with PCa.
Materials and methods. The study included 492 patients with histologically confirmed stage I–IV PCa. All patients were examined with PET/CT with 18F-PSMA-1007 during staging work-up, therapy, follow-up, and restaging in case of progression. The imaging was performed on a GE Discovery PET/CT 710 scanner.
Results. Twenty-four (4.9%) patients had multiple primary malignancies of various localizations. In 8 (1.6%) of them, clear-cell RCC was diagnosed. The median age was 73.3 years. In most cases, the tumor was synchronous (6 [75%] patients) and metachronous (2 [25%] patients). The tumor was localized in the left kidney in 6 (62.5%) patients and the right kidney in 3 (37.5%) patients. The tumor was diagnosed in the upper segment in 5 cases, in the anterior segment, in 2 patients, and 1 patient had the tumor in the lower segment. The size of the primary tumor averaged 33.8 mm, corresponding to the T1a category. The median SUVmax in the tumor was 17.92. Histological examination of tumor biopsy specimens showed clear-cell RCC. In the first stage, surgical treatment was performed on 7 patients: 2 had laparoscopic nephrectomy, and 5 had organ-sparing interventions with an endoscopic approach. Systemic therapy was administered to 1 patient.
Conclusion. PET/CT with 18F-PSMA-1007 is an alternative method for assessing the extension of the tumor process in patients with PCa during therapy and diagnosis. It detected primary multiple renal tumors in 1.6% of patients. The tumor size averaged 33.8 mm, corresponding to the T1a stage. In such cases, treatment should begin with surgery, allowing for the tailoring of treatment options.
Keywords: prostate cancer, clear cell renal cell carcinoma, diagnosis, combined positron emission and X-ray computed tomography with 18F-PSMA-1007
Цель. Оценить возможности ПЭТ/КТ с 18F-PSMA-1007 для диагностики первичных опухолей почек у больных РПЖ.
Материалы и методы. Под наблюдением находились 492 пациента с гистологически подтвержденным РПЖ I–IV стадий. Всем больным проводилось обследование с помощью ПЭТ/КТ с 18F-PSMA-1007 на этапе стадирования, в процессе терапии, диспансерном наблюдении и рестадировании при прогрессировании. Исследование выполнялось на аппарате GE Discovery PET/CT 710.
Результаты. У 24 (4,9%) пациентов выявлены первично-множественные злокачественные опухоли различных локализаций. Среди них светлоклеточный ПКР диагностирован в 8 (1,6%) наблюдениях. Медиана возраста составила 73,3 года. В большинстве случаев – у 6 (75%) пациентов – опухоль являлась синхронной и у 2 (25%) имела метахронный характер. Чаще всего опухолевый процесс локализовался в левой почке – 6 (62,5%), а в правой – у 3 (37,5%) больных. В верхнем сегменте опухоль диагностирована в 5 случаях, в переднем – у 2 пациентов и в нижнем сегменте – у 1. Величина первичной опухоли в среднем составляла 33,8 мм, что соответствует категории Т1а. Медиана SUVmax в опухоли – 17,92. При гистологическом исследовании биоптатов из новообразования у всех выявлен светлоклеточный ПКР. На I этапе хирургическое лечение выполнено 7 больным: лапароскопическая нефрэктомия – 2 пациентам и органосохраняющие вмешательства эндоскопическим доступом – 5. Системная терапия назначена 1 больному.
Заключение. ПЭТ/КТ с 18F-PSMA-1007 является альтернативным методом оценки распространенности опухолевого процесса у больных РПЖ на этапах лечебно-диагностического процесса. Он позволяет в 1,6% случаев выявить первично-множественные опухоли почек. Их величина в среднем составила 33,8 мм, что соответствует стадии Т1а. В таких случаях лечение необходимо начинать с хирургического вмешательства, что позволяет персонализировать лечебные опции.
Ключевые слова: рак предстательной железы, светлоклеточный почечно-клеточный рак, диагностика, комбинированная позитронно- эмиссионная и рентгеновская компьютерная томография с 18F-PSMA-1007
________________________________________________
Aim. To evaluate the capabilities of PET/CT with 18F-PSMA-1007 for the diagnosis of primary renal tumors in patients with PCa.
Materials and methods. The study included 492 patients with histologically confirmed stage I–IV PCa. All patients were examined with PET/CT with 18F-PSMA-1007 during staging work-up, therapy, follow-up, and restaging in case of progression. The imaging was performed on a GE Discovery PET/CT 710 scanner.
Results. Twenty-four (4.9%) patients had multiple primary malignancies of various localizations. In 8 (1.6%) of them, clear-cell RCC was diagnosed. The median age was 73.3 years. In most cases, the tumor was synchronous (6 [75%] patients) and metachronous (2 [25%] patients). The tumor was localized in the left kidney in 6 (62.5%) patients and the right kidney in 3 (37.5%) patients. The tumor was diagnosed in the upper segment in 5 cases, in the anterior segment, in 2 patients, and 1 patient had the tumor in the lower segment. The size of the primary tumor averaged 33.8 mm, corresponding to the T1a category. The median SUVmax in the tumor was 17.92. Histological examination of tumor biopsy specimens showed clear-cell RCC. In the first stage, surgical treatment was performed on 7 patients: 2 had laparoscopic nephrectomy, and 5 had organ-sparing interventions with an endoscopic approach. Systemic therapy was administered to 1 patient.
Conclusion. PET/CT with 18F-PSMA-1007 is an alternative method for assessing the extension of the tumor process in patients with PCa during therapy and diagnosis. It detected primary multiple renal tumors in 1.6% of patients. The tumor size averaged 33.8 mm, corresponding to the T1a stage. In such cases, treatment should begin with surgery, allowing for the tailoring of treatment options.
Keywords: prostate cancer, clear cell renal cell carcinoma, diagnosis, combined positron emission and X-ray computed tomography with 18F-PSMA-1007
Полный текст
Список литературы
1. Global Cancer Observatory (GCO). 2022. Available at: https://gco.iarc.fr/en. Accessed: 12.11.2024.
2. Sadaghiani MS, Baskaran S, Gorin MA, et al. Utility of PSMA PET/CT in staging and restaging of renal cell carcinoma: a systematic review and metaanalysis. J Nucl Med. 2024;jnumed.124.267417. DOI:10.2967/jnumed.124.267417
3. Muselaers S, Erdem S, Bertolo R, et al. On Behalf Of The European Association Of Urology Eau Young Academic Urologists Yau Renal Cancer Working Group. PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature. J Clin Med. 2022;11(7):1829. DOI:10.3390/jcm11071829
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843-52. DOI:10.1016/s0094-0143(03)00056-9
5. Marchioni M, Sountoulides P, Furlan M, et al. Management of local recurrence after radical nephrectomy: Surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. Int Urol Nephrol. 2021;53:2273-80. DOI:10.1007/s11255-021-02966-9
6. Crocerossa F, Marchioni M, Novara G, et al. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis. J Urol. 2021;205:356-69. DOI:10.1097/JU.0000000000001369
7. Spatz S, Tolkach Y, Jung K, et al. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol. 2018;199:370-7. DOI:10.1016/j.juro.2017.08.079
8. Van de Wiele C, Sathekge M, de Spiegeleer B, et al. PSMA expression on neovasculature of solid tumors. Histol Histopathol. 2020;35:919-27.
9. Demirci E, Ocak M, Kabasakal L, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461-2. DOI:10.1007/s00259-014-2766-y
10. Gao J, Xu Q, Fu Y, et al. Comprehensive evaluation of (68)Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:561-9. DOI:10.1007/s00259-020-04916-6
11. Rhee H, Blazak J, Tham CM, et al. Pilot study: Use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 2016;6:76. DOI:10.1186/s13550-016-0231-6
12. Sawicki LM, Buchbender C, Boos J, et al. Diagnostic potential of PET/CT using a (68)Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: Initial experience. Eur J Nucl Med Mol Imaging. 2017;44:102-7. DOI:10.1007/s00259-016-3360-2
13. Yin Y, Campbell SP, Markowski MC, et al. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [(18)F]DCFPyL PET/CT. Mol Imaging Biol. 2019;21:567-73. DOI:10.1007/s11307-018-1271-2
14. Spatz S, Tolkach Y, Jung K, et al. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol. 2018;199:370-7. DOI:10.1016/j.juro.2017.08.079
15. Tariq A, Kwok M, Pearce A, et al. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Urol Oncol. 2022;40. DOI:10.1016/j.urolonc.2021.11.006
16. Barocas DA, Rabbani F, Scherr DS, Vaughan ED. A population-based study of renal cell carcinoma and prostate cancer in the same patients. BJU Int. 2006;97(1):33-6. DOI:10.1111/j.1464-410X.2005.05880.x
17. Gühne F, Seifert P, Theis B, et al. PSMA-PET/CT in patients with recurrent clear cell renal cell carcinoma: Histopathological correlations of imaging findings. Diagnostics. 2021;11(7):1142. DOI:10.3390/diagnostics11071142
18. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7(5B):927-35.
19. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2(9):1445-51.
20. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50(4):472-83. DOI:10.1111/j.1365-2559.2007.02635.x
21. Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26(14):5310-24. DOI:10.1128/MCB.00084-06
22. Cohen В, Zhou M. Molecular Genetics of Familial Renal Cell Carcinoma Syndromes Clin. Lab Med. 2025;25:259-77. DOI:10.1016/J.CLL.2005.01.003
23. Ahn T, Roberts MJ, Abduljabar A, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol. 2019;21(5):799-807. DOI:10.1007/s11307-018-01307-0
24. Baraban EG, Ged Y, Singla N, et al. Vascular expression of prostate-specific membrane antigen (PSMA) in MiTF family translocation renal cell carcinoma and related neoplasms. Appl Immunohistochem Mol Morphol. 2023;31:544-9.
25. Salas Fragomeni RA, Amir T, Sheikhbahaei S, et al. Imaging of nonprostate cancers using PSMA-targeted radiotracers: Rationale, current state of the field, and a call to arms. J Nucl Med. 2018;59(6):871-7. DOI:10.2967/jnumed.117.203570
26. Wang G, Zhou M, Zang J, et al. A pilot study of 68 ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma. EJNMMI Res. 2022;12(1):52. DOI:10.1186/s13550-022-00922-x
27. Jiao D, Li Y, Yang F, et al. Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma. Clin Transl Gastroenterol. 2019;10:e00041-7. DOI:10.14309/ctg.0000000000000041
28. Psutka SP, Master VA. Role of metastasis-directed treatment in kidney cancer. Cancer. 2018;124:3641-55.
29. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology JNCCN. J Natl Compr Cancer Netw. 2022;20(1):71-90.
30. Brufau BP, Cerqueda CS, Villalba LB, et al. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. Radiographics. 2013;33:1691-716.
31. Aggarwal P, Singh H, Das CK, et al. Potential role of 68Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study. Eur J Radiol. 2024;170:111218. DOI:10.1016/j.ejrad.2023.111218
32. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674-82.
33. Wang G, Li L, Wang J, et al. Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1499-509.
34. Holzgreve A, Unterrainer M, Calais J, et al. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023;50:3750-4. DOI:10.1007/s00259-023-06332-y
35. Urso L, Castello A, Rocca GC, et al. Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022;148(6):1299-311. DOI:10.1007/s00432-022-03958-7
36. Li Y, Zheng R, Zhang Y, et al. Special issue “The advance of solid tumor research in China”: 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma. Int J Cancer. 2023;152(1):42-50.
37. Klein Nulent TJW, van Es RJJ, Willems SM, et al. First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Res. 2021;11(1):126. DOI:10.1186/s13550-021-00866-8
38. Siva S, Callahan J, Pryor D, et al. Utility of (68) Ga prostate specific membrane antigen – positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat. Oncol. 2017;61:372-8. DOI:10.1111/1754-9485.12590
39. Rizzo A, Racca M, Dall’Armellina S, et al. The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers. 2023;15:355. DOI:10.3390/cancers15020355
2. Sadaghiani MS, Baskaran S, Gorin MA, et al. Utility of PSMA PET/CT in staging and restaging of renal cell carcinoma: a systematic review and metaanalysis. J Nucl Med. 2024;jnumed.124.267417. DOI:10.2967/jnumed.124.267417
3. Muselaers S, Erdem S, Bertolo R, et al. On Behalf Of The European Association Of Urology Eau Young Academic Urologists Yau Renal Cancer Working Group. PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature. J Clin Med. 2022;11(7):1829. DOI:10.3390/jcm11071829
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843-52. DOI:10.1016/s0094-0143(03)00056-9
5. Marchioni M, Sountoulides P, Furlan M, et al. Management of local recurrence after radical nephrectomy: Surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. Int Urol Nephrol. 2021;53:2273-80. DOI:10.1007/s11255-021-02966-9
6. Crocerossa F, Marchioni M, Novara G, et al. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis. J Urol. 2021;205:356-69. DOI:10.1097/JU.0000000000001369
7. Spatz S, Tolkach Y, Jung K, et al. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol. 2018;199:370-7. DOI:10.1016/j.juro.2017.08.079
8. Van de Wiele C, Sathekge M, de Spiegeleer B, et al. PSMA expression on neovasculature of solid tumors. Histol Histopathol. 2020;35:919-27.
9. Demirci E, Ocak M, Kabasakal L, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461-2. DOI:10.1007/s00259-014-2766-y
10. Gao J, Xu Q, Fu Y, et al. Comprehensive evaluation of (68)Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:561-9. DOI:10.1007/s00259-020-04916-6
11. Rhee H, Blazak J, Tham CM, et al. Pilot study: Use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 2016;6:76. DOI:10.1186/s13550-016-0231-6
12. Sawicki LM, Buchbender C, Boos J, et al. Diagnostic potential of PET/CT using a (68)Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: Initial experience. Eur J Nucl Med Mol Imaging. 2017;44:102-7. DOI:10.1007/s00259-016-3360-2
13. Yin Y, Campbell SP, Markowski MC, et al. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [(18)F]DCFPyL PET/CT. Mol Imaging Biol. 2019;21:567-73. DOI:10.1007/s11307-018-1271-2
14. Spatz S, Tolkach Y, Jung K, et al. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol. 2018;199:370-7. DOI:10.1016/j.juro.2017.08.079
15. Tariq A, Kwok M, Pearce A, et al. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Urol Oncol. 2022;40. DOI:10.1016/j.urolonc.2021.11.006
16. Barocas DA, Rabbani F, Scherr DS, Vaughan ED. A population-based study of renal cell carcinoma and prostate cancer in the same patients. BJU Int. 2006;97(1):33-6. DOI:10.1111/j.1464-410X.2005.05880.x
17. Gühne F, Seifert P, Theis B, et al. PSMA-PET/CT in patients with recurrent clear cell renal cell carcinoma: Histopathological correlations of imaging findings. Diagnostics. 2021;11(7):1142. DOI:10.3390/diagnostics11071142
18. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7(5B):927-35.
19. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2(9):1445-51.
20. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50(4):472-83. DOI:10.1111/j.1365-2559.2007.02635.x
21. Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26(14):5310-24. DOI:10.1128/MCB.00084-06
22. Cohen В, Zhou M. Molecular Genetics of Familial Renal Cell Carcinoma Syndromes Clin. Lab Med. 2025;25:259-77. DOI:10.1016/J.CLL.2005.01.003
23. Ahn T, Roberts MJ, Abduljabar A, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol. 2019;21(5):799-807. DOI:10.1007/s11307-018-01307-0
24. Baraban EG, Ged Y, Singla N, et al. Vascular expression of prostate-specific membrane antigen (PSMA) in MiTF family translocation renal cell carcinoma and related neoplasms. Appl Immunohistochem Mol Morphol. 2023;31:544-9.
25. Salas Fragomeni RA, Amir T, Sheikhbahaei S, et al. Imaging of nonprostate cancers using PSMA-targeted radiotracers: Rationale, current state of the field, and a call to arms. J Nucl Med. 2018;59(6):871-7. DOI:10.2967/jnumed.117.203570
26. Wang G, Zhou M, Zang J, et al. A pilot study of 68 ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma. EJNMMI Res. 2022;12(1):52. DOI:10.1186/s13550-022-00922-x
27. Jiao D, Li Y, Yang F, et al. Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma. Clin Transl Gastroenterol. 2019;10:e00041-7. DOI:10.14309/ctg.0000000000000041
28. Psutka SP, Master VA. Role of metastasis-directed treatment in kidney cancer. Cancer. 2018;124:3641-55.
29. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology JNCCN. J Natl Compr Cancer Netw. 2022;20(1):71-90.
30. Brufau BP, Cerqueda CS, Villalba LB, et al. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. Radiographics. 2013;33:1691-716.
31. Aggarwal P, Singh H, Das CK, et al. Potential role of 68Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study. Eur J Radiol. 2024;170:111218. DOI:10.1016/j.ejrad.2023.111218
32. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674-82.
33. Wang G, Li L, Wang J, et al. Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1499-509.
34. Holzgreve A, Unterrainer M, Calais J, et al. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023;50:3750-4. DOI:10.1007/s00259-023-06332-y
35. Urso L, Castello A, Rocca GC, et al. Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022;148(6):1299-311. DOI:10.1007/s00432-022-03958-7
36. Li Y, Zheng R, Zhang Y, et al. Special issue “The advance of solid tumor research in China”: 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma. Int J Cancer. 2023;152(1):42-50.
37. Klein Nulent TJW, van Es RJJ, Willems SM, et al. First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Res. 2021;11(1):126. DOI:10.1186/s13550-021-00866-8
38. Siva S, Callahan J, Pryor D, et al. Utility of (68) Ga prostate specific membrane antigen – positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat. Oncol. 2017;61:372-8. DOI:10.1111/1754-9485.12590
39. Rizzo A, Racca M, Dall’Armellina S, et al. The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers. 2023;15:355. DOI:10.3390/cancers15020355
2. Sadaghiani MS, Baskaran S, Gorin MA, et al. Utility of PSMA PET/CT in staging and restaging of renal cell carcinoma: a systematic review and metaanalysis. J Nucl Med. 2024;jnumed.124.267417. DOI:10.2967/jnumed.124.267417
3. Muselaers S, Erdem S, Bertolo R, et al. On Behalf Of The European Association Of Urology Eau Young Academic Urologists Yau Renal Cancer Working Group. PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature. J Clin Med. 2022;11(7):1829. DOI:10.3390/jcm11071829
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843-52. DOI:10.1016/s0094-0143(03)00056-9
5. Marchioni M, Sountoulides P, Furlan M, et al. Management of local recurrence after radical nephrectomy: Surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. Int Urol Nephrol. 2021;53:2273-80. DOI:10.1007/s11255-021-02966-9
6. Crocerossa F, Marchioni M, Novara G, et al. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis. J Urol. 2021;205:356-69. DOI:10.1097/JU.0000000000001369
7. Spatz S, Tolkach Y, Jung K, et al. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol. 2018;199:370-7. DOI:10.1016/j.juro.2017.08.079
8. Van de Wiele C, Sathekge M, de Spiegeleer B, et al. PSMA expression on neovasculature of solid tumors. Histol Histopathol. 2020;35:919-27.
9. Demirci E, Ocak M, Kabasakal L, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461-2. DOI:10.1007/s00259-014-2766-y
10. Gao J, Xu Q, Fu Y, et al. Comprehensive evaluation of (68)Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:561-9. DOI:10.1007/s00259-020-04916-6
11. Rhee H, Blazak J, Tham CM, et al. Pilot study: Use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 2016;6:76. DOI:10.1186/s13550-016-0231-6
12. Sawicki LM, Buchbender C, Boos J, et al. Diagnostic potential of PET/CT using a (68)Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: Initial experience. Eur J Nucl Med Mol Imaging. 2017;44:102-7. DOI:10.1007/s00259-016-3360-2
13. Yin Y, Campbell SP, Markowski MC, et al. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [(18)F]DCFPyL PET/CT. Mol Imaging Biol. 2019;21:567-73. DOI:10.1007/s11307-018-1271-2
14. Spatz S, Tolkach Y, Jung K, et al. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol. 2018;199:370-7. DOI:10.1016/j.juro.2017.08.079
15. Tariq A, Kwok M, Pearce A, et al. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Urol Oncol. 2022;40. DOI:10.1016/j.urolonc.2021.11.006
16. Barocas DA, Rabbani F, Scherr DS, Vaughan ED. A population-based study of renal cell carcinoma and prostate cancer in the same patients. BJU Int. 2006;97(1):33-6. DOI:10.1111/j.1464-410X.2005.05880.x
17. Gühne F, Seifert P, Theis B, et al. PSMA-PET/CT in patients with recurrent clear cell renal cell carcinoma: Histopathological correlations of imaging findings. Diagnostics. 2021;11(7):1142. DOI:10.3390/diagnostics11071142
18. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7(5B):927-35.
19. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2(9):1445-51.
20. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50(4):472-83. DOI:10.1111/j.1365-2559.2007.02635.x
21. Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26(14):5310-24. DOI:10.1128/MCB.00084-06
22. Cohen В, Zhou M. Molecular Genetics of Familial Renal Cell Carcinoma Syndromes Clin. Lab Med. 2025;25:259-77. DOI:10.1016/J.CLL.2005.01.003
23. Ahn T, Roberts MJ, Abduljabar A, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol. 2019;21(5):799-807. DOI:10.1007/s11307-018-01307-0
24. Baraban EG, Ged Y, Singla N, et al. Vascular expression of prostate-specific membrane antigen (PSMA) in MiTF family translocation renal cell carcinoma and related neoplasms. Appl Immunohistochem Mol Morphol. 2023;31:544-9.
25. Salas Fragomeni RA, Amir T, Sheikhbahaei S, et al. Imaging of nonprostate cancers using PSMA-targeted radiotracers: Rationale, current state of the field, and a call to arms. J Nucl Med. 2018;59(6):871-7. DOI:10.2967/jnumed.117.203570
26. Wang G, Zhou M, Zang J, et al. A pilot study of 68 ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma. EJNMMI Res. 2022;12(1):52. DOI:10.1186/s13550-022-00922-x
27. Jiao D, Li Y, Yang F, et al. Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma. Clin Transl Gastroenterol. 2019;10:e00041-7. DOI:10.14309/ctg.0000000000000041
28. Psutka SP, Master VA. Role of metastasis-directed treatment in kidney cancer. Cancer. 2018;124:3641-55.
29. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology JNCCN. J Natl Compr Cancer Netw. 2022;20(1):71-90.
30. Brufau BP, Cerqueda CS, Villalba LB, et al. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. Radiographics. 2013;33:1691-716.
31. Aggarwal P, Singh H, Das CK, et al. Potential role of 68Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study. Eur J Radiol. 2024;170:111218. DOI:10.1016/j.ejrad.2023.111218
32. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674-82.
33. Wang G, Li L, Wang J, et al. Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1499-509.
34. Holzgreve A, Unterrainer M, Calais J, et al. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023;50:3750-4. DOI:10.1007/s00259-023-06332-y
35. Urso L, Castello A, Rocca GC, et al. Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022;148(6):1299-311. DOI:10.1007/s00432-022-03958-7
36. Li Y, Zheng R, Zhang Y, et al. Special issue “The advance of solid tumor research in China”: 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma. Int J Cancer. 2023;152(1):42-50.
37. Klein Nulent TJW, van Es RJJ, Willems SM, et al. First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Res. 2021;11(1):126. DOI:10.1186/s13550-021-00866-8
38. Siva S, Callahan J, Pryor D, et al. Utility of (68) Ga prostate specific membrane antigen – positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat. Oncol. 2017;61:372-8. DOI:10.1111/1754-9485.12590
39. Rizzo A, Racca M, Dall’Armellina S, et al. The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers. 2023;15:355. DOI:10.3390/cancers15020355
________________________________________________
2. Sadaghiani MS, Baskaran S, Gorin MA, et al. Utility of PSMA PET/CT in staging and restaging of renal cell carcinoma: a systematic review and metaanalysis. J Nucl Med. 2024;jnumed.124.267417. DOI:10.2967/jnumed.124.267417
3. Muselaers S, Erdem S, Bertolo R, et al. On Behalf Of The European Association Of Urology Eau Young Academic Urologists Yau Renal Cancer Working Group. PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature. J Clin Med. 2022;11(7):1829. DOI:10.3390/jcm11071829
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843-52. DOI:10.1016/s0094-0143(03)00056-9
5. Marchioni M, Sountoulides P, Furlan M, et al. Management of local recurrence after radical nephrectomy: Surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. Int Urol Nephrol. 2021;53:2273-80. DOI:10.1007/s11255-021-02966-9
6. Crocerossa F, Marchioni M, Novara G, et al. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis. J Urol. 2021;205:356-69. DOI:10.1097/JU.0000000000001369
7. Spatz S, Tolkach Y, Jung K, et al. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol. 2018;199:370-7. DOI:10.1016/j.juro.2017.08.079
8. Van de Wiele C, Sathekge M, de Spiegeleer B, et al. PSMA expression on neovasculature of solid tumors. Histol Histopathol. 2020;35:919-27.
9. Demirci E, Ocak M, Kabasakal L, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461-2. DOI:10.1007/s00259-014-2766-y
10. Gao J, Xu Q, Fu Y, et al. Comprehensive evaluation of (68)Ga-PSMA-11 PET/CT parameters for discriminating pathological characteristics in primary clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:561-9. DOI:10.1007/s00259-020-04916-6
11. Rhee H, Blazak J, Tham CM, et al. Pilot study: Use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 2016;6:76. DOI:10.1186/s13550-016-0231-6
12. Sawicki LM, Buchbender C, Boos J, et al. Diagnostic potential of PET/CT using a (68)Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: Initial experience. Eur J Nucl Med Mol Imaging. 2017;44:102-7. DOI:10.1007/s00259-016-3360-2
13. Yin Y, Campbell SP, Markowski MC, et al. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [(18)F]DCFPyL PET/CT. Mol Imaging Biol. 2019;21:567-73. DOI:10.1007/s11307-018-1271-2
14. Spatz S, Tolkach Y, Jung K, et al. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol. 2018;199:370-7. DOI:10.1016/j.juro.2017.08.079
15. Tariq A, Kwok M, Pearce A, et al. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison. Urol Oncol. 2022;40. DOI:10.1016/j.urolonc.2021.11.006
16. Barocas DA, Rabbani F, Scherr DS, Vaughan ED. A population-based study of renal cell carcinoma and prostate cancer in the same patients. BJU Int. 2006;97(1):33-6. DOI:10.1111/j.1464-410X.2005.05880.x
17. Gühne F, Seifert P, Theis B, et al. PSMA-PET/CT in patients with recurrent clear cell renal cell carcinoma: Histopathological correlations of imaging findings. Diagnostics. 2021;11(7):1142. DOI:10.3390/diagnostics11071142
18. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7(5B):927-35.
19. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2(9):1445-51.
20. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50(4):472-83. DOI:10.1111/j.1365-2559.2007.02635.x
21. Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol. 2006;26(14):5310-24. DOI:10.1128/MCB.00084-06
22. Cohen В, Zhou M. Molecular Genetics of Familial Renal Cell Carcinoma Syndromes Clin. Lab Med. 2025;25:259-77. DOI:10.1016/J.CLL.2005.01.003
23. Ahn T, Roberts MJ, Abduljabar A, et al. A review of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) in renal cell carcinoma (RCC). Mol Imaging Biol. 2019;21(5):799-807. DOI:10.1007/s11307-018-01307-0
24. Baraban EG, Ged Y, Singla N, et al. Vascular expression of prostate-specific membrane antigen (PSMA) in MiTF family translocation renal cell carcinoma and related neoplasms. Appl Immunohistochem Mol Morphol. 2023;31:544-9.
25. Salas Fragomeni RA, Amir T, Sheikhbahaei S, et al. Imaging of nonprostate cancers using PSMA-targeted radiotracers: Rationale, current state of the field, and a call to arms. J Nucl Med. 2018;59(6):871-7. DOI:10.2967/jnumed.117.203570
26. Wang G, Zhou M, Zang J, et al. A pilot study of 68 ga-PSMA-617 PET/CT imaging and 177Lu-EB-PSMA-617 radioligand therapy in patients with adenoid cystic carcinoma. EJNMMI Res. 2022;12(1):52. DOI:10.1186/s13550-022-00922-x
27. Jiao D, Li Y, Yang F, et al. Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma. Clin Transl Gastroenterol. 2019;10:e00041-7. DOI:10.14309/ctg.0000000000000041
28. Psutka SP, Master VA. Role of metastasis-directed treatment in kidney cancer. Cancer. 2018;124:3641-55.
29. Motzer RJ, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology JNCCN. J Natl Compr Cancer Netw. 2022;20(1):71-90.
30. Brufau BP, Cerqueda CS, Villalba LB, et al. Metastatic renal cell carcinoma: radiologic findings and assessment of response to targeted antiangiogenic therapy by using multidetector CT. Radiographics. 2013;33:1691-716.
31. Aggarwal P, Singh H, Das CK, et al. Potential role of 68Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study. Eur J Radiol. 2024;170:111218. DOI:10.1016/j.ejrad.2023.111218
32. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27:3674-82.
33. Wang G, Li L, Wang J, et al. Head-to-head comparison of [68Ga]Ga-P16-093 and 2-[18F]FDG PET/CT in patients with clear cell renal cell carcinoma: a pilot study. Eur J Nucl Med Mol Imaging. 2023;50:1499-509.
34. Holzgreve A, Unterrainer M, Calais J, et al. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023;50:3750-4. DOI:10.1007/s00259-023-06332-y
35. Urso L, Castello A, Rocca GC, et al. Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022;148(6):1299-311. DOI:10.1007/s00432-022-03958-7
36. Li Y, Zheng R, Zhang Y, et al. Special issue “The advance of solid tumor research in China”: 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma. Int J Cancer. 2023;152(1):42-50.
37. Klein Nulent TJW, van Es RJJ, Willems SM, et al. First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Res. 2021;11(1):126. DOI:10.1186/s13550-021-00866-8
38. Siva S, Callahan J, Pryor D, et al. Utility of (68) Ga prostate specific membrane antigen – positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat. Oncol. 2017;61:372-8. DOI:10.1111/1754-9485.12590
39. Rizzo A, Racca M, Dall’Armellina S, et al. The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers. 2023;15:355. DOI:10.3390/cancers15020355
Авторы
Н.А. Огнерубов*1, О.О. Мирсалимова2, Т.С. Антипова2
1ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
2Федеральная сеть центров ядерной медицины «ПЭТ-технолоджи», Москва, Россия
*ognerubov_n.a@mail.ru
1Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
2PET-Technology, Moscow, Russia
*ognerubov_n.a@mail.ru
1ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
2Федеральная сеть центров ядерной медицины «ПЭТ-технолоджи», Москва, Россия
*ognerubov_n.a@mail.ru
________________________________________________
1Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
2PET-Technology, Moscow, Russia
*ognerubov_n.a@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.